Investment
Features
FeesSafety
Academy
More
Pluang+

Compare HubSpot Inc (HUBS) vs Revvity Inc (RVTY) Price & Performance

HubSpot IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

HubSpot Inc vs Revvity Inc — how do they compare? HubSpot Inc trades at $228.3 (market cap $11.56B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Revvity Inc for 12 Days on average.

HUBSRVTY
Market Cap
$11.56B$16.98B
Volume
1,891,2871,456,900
Sector
TechnologyHealth
52-Week High
$494.58$157.36
52-Week Low
$170.39$82.26
Typical Hold Time
78 Days12 Days
Enterprise Value
$10.46B$19.30B
Dividend Yield
—0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

HubSpot Inc

HubSpot (HUBS) trades at $228.30, up 3.63% with strong technical momentum and bullish moving averages. The company demonstrates robust revenue growth, reaching $3.13B in 2025 with improving profitability, though valuation ratios remain elevated. Recent analyst day highlighted AI strategy enhancements and margin expansion targets, while institutional buying and positive earnings beats support investor confidence.

Outlook remains positive with 57% analyst buy ratings and $243.65 consensus target, though risks include high P/E ratio, competitive pressures, and potential AI disruption concerns. The stock offers growth exposure with solid cash flow generation but requires monitoring of execution against ambitious margin targets.

Revvity Inc

Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.

The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HUBS
1% Buy99% Sell
Avg holding period · 78 Days
RVTY
0% Buy100% Sell
Avg holding period · 12 Days

Top news

Latest headlines on both assets

About HubSpot Inc

HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.

Read more on HUBS →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →